IGF2BP3 and hepatocellular carcinoma: In lenvatinib-resistant hepatocellular carcinoma, proteomic analysis showed elevated lactylation modifications, especially IGF2BP3 K76la, which enhances serine metabolism reprogramming and m6A modification, improving antioxidant ability and lenvatinib resistance (Lu et al., 2024).